Additionally, our results also suggest that bone destruction caused by tumor invasion in human OSCC is through RANKL-RANK/NF-κB/NFATc1 pathway36, which can be suppressed by sorafenib through releasing OPG from osteoblasts to suppress RANKL binding to RANK (Fig. 5). The gene discussed is NFATC1; the disease is neoplasm.